Thomas Bollyky1, Aaron S Kesselheim1. 1. From the Council on Foreign Relations, Washington, DC (T.B.); and the Program on Regulation, Therapeutics, and Law (PORTAL), Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston (A.S.K.).